ONCAlert | Upfront Therapy for mRCC

AML VIEW MORE >>

In an interview with Targeted Oncology, Rajneesh Nath, MD, discussed the background and rationale for the phase III SIERRA trial. He also explained what this research means for the treatment landscape of acute myeloid leukemia. 

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.